Related Experiment Videos
Overview of Taxol safety
N Onetto1, R Canetta, B Winograd
1Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Conn. 06492-7660.
Journal of the National Cancer Institute. Monographs
|January 1, 1993
Summary
Taxol (paclitaxel) is generally safe as a single intravenous agent, with myelosuppression (neutropenia) being the main dose-limiting toxicity. Premedication effectively managed hypersensitivity reactions, and other side effects were typically manageable.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Taxol (paclitaxel) is an intravenously administered chemotherapy agent used in cancer treatment.
- Establishing the safety profile of single-agent Taxol is crucial for its clinical application.
Purpose of the Study:
- To establish the safety profile of intravenous Taxol as a single agent.
- To identify dose-limiting toxicities and manageable adverse events in patients with solid tumors.
Main Methods:
- Analysis of safety data from 655 patients across nine Phase I and eight Phase II studies.
- Evaluation of adverse events, including myelosuppression, hypersensitivity reactions, cardiovascular effects, and neuropathy.
Main Results:
- Neutropenia was the dose-limiting toxicity, influenced by administration schedule (less severe with 3-hour infusion).
- Severe hypersensitivity reactions were controlled with a premedication regimen (dexamethasone, antihistamine, H2 blocker).
- Cardiovascular toxicities were minimal; peripheral neuropathy was usually mild to moderate and rarely led to discontinuation.
Conclusions:
- Intravenous Taxol as a single agent has an established safety profile in patients with solid tumors.
- Neutropenia management and premedication strategies are key to safe Taxol administration.
- Most adverse events are manageable, supporting its role in cancer therapy.